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Abstract
Background: Like many other cancer patients, most pancreatic carcinoma patients suffer from severe weight loss.
As shown in numerous studies with fish oil (FO) supplementation, a minimum daily intake of 1.5 g n-3-fatty acids
(n-3-FA) contributes to weight stabilization and improvement of quality of life (QoL) of cancer patients. Given n-3-
FA not as triglycerides (FO), but mainly bound to marine phospholipids (MPL), weight stabilization and
improvement of QoL has already been seen at much lower doses of n-3-FA (0,3 g), and MPL were much better
tolerated. The objective of this double-blind randomized controlled trial was to compare low dose MPL and FO
formulations, which had the same n-3-FA amount and composition, on weight and appetite stabilization, global
health enhancement (QoL), and plasma FA-profiles in patients suffering from pancreatic cancer.
Methods: Sixty pancreatic cancer patients were included into the study and randomized to take either FO- or MPL
supplementation. Patients were treated with 0.3 g of n-3-fatty acids per day over six weeks. Since the n-3-FA
content of FO is usually higher than that of MPL, FO was diluted with 40% of medium chain triglycerides (MCT) to
achieve the same capsule size in both intervention groups and therefore assure blinding. Routine blood parameters,
lipid profiles, body weight, and appetite were measured before and after intervention. Patient compliance was
assessed through a patient diary. Quality of life and nutritional habits were assessed with validated questionnaires
(EORTC-QLQ-C30, PAN26). Thirty one patients finalized the study protocol and were analyzed (per-protocol-analysis).
Results: Intervention with low dose n-3-FAs, either as FO or MPL supplementation, resulted in similar and
promising weight and appetite stabilization in pancreatic cancer patients. MPL capsules were slightly better
tolerated and showed fewer side effects, when compared to FO supplementation.
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Conclusion: The similar effects between both interventions were unexpected but reliable, since the MPL and FO
formulations caused identical increases of n-3-FAs in plasma lipids of included patients after supplementation. The
effects of FO with very low n-3-FA content might be explained by the addition of MCT. The results of this study
suggest the need for further investigations of marine phospholipids for the improvement of QoL of cancer patients,
optionally in combination with MCT.
Keywords: Pancreatic cancer, Cancer cachexia, Marine phospholipids, Fish oil, Medium chain triglycerides, N-3-fatty
acids, Weight stabilization, Randomized controlled trial
Background
Cancer may induce severe weight loss (cancer cachexia),
which is a common problem of pancreatic cancer patients.
It is defined as a continuous and unintended weight loss
of at least 5% since first diagnosis over a period of six
months [1]. Approximately 80% of all patients with ad-
vanced pancreatic cancer die because of cancer cachexia
[1]. This condition is usually accompanied with appetite
loss and lower quality of life (QoL) [2]. Various studies
have shown that patients who achieved weight gain
during cancer cachexia had lower mortality rates [3].
Several reasons for cancer cachexia have been reported.
One of the most important reasons is the tumor asso-
ciated inflammatory response, which is a multifactori-
ally induced metabolic disorder. The activity of pro-
inflammatory mediators like the cytokines TNFα, IL-1
and IL-6 as well as INF-γ lead to catabolic processes
like lipolysis, proteolysis, and increased resting energy
expenditure [2, 4–6] The cytokine release stimulates
the production of pro-inflammatory eicosanoids like
PGE2, PGF2a, PGD2, PGI2 and TXA2 – all bioactive
lipid-second-messengers [7, 8] derived from arachi-
donic acid (AA), which is a n-6-polyunsaturated fatty
acid (20:4 (n − 6)).
AA is an important component of cellular membranes,
where it is predominantly bound to the 2-position of
membrane forming phospholipids. Especially in inflam-
matory events, AA is cleaved from the phospholipids
and serves at least in part for pro-inflammatory eicosa-
noid production and hence contributes to the develop-
ment of cancer cachexia.
If the pro-inflammatory AA (a n-6-FA) are partly re-
placed by the anti-inflammatory n-3-polyunsaturated fatty
acids docosahexaenoic acid (DHA) and eicosapentaenoic
acid (EPA), i.e. by consuming higher amounts of DHA
and EPA, then the n-3-FAs will compete with AA for bio-
synthesis of lipid-second-messengers. In contrast to AA,
metabolic transformation of DHA and EPA results in the
production of anti-inflammatory eicosanoids like pros-
taglandins of the first and third class and leukotrienes
of the fifth class. This displacement of AA in the
phospholipid component of cellular membranes by
EPA or DHA results in reduced inflammatory response
induced by pro-inflammatory cytokines and may there-
fore reduce cancer cachexia [9–12]
The anti-inflammatory effects of oral n-3-FA – mostly
given as fish oil (FO) - have broadly been investigated.
Barber has shown that EPA, given as nutritional supple-
ment, increased weight of 20 pancreatic carcinoma pa-
tients [13], and a similar effect has been shown by
Wigmore et al. [14] In a meta-analysis, Colomer et al. [12]
summarized some high quality studies focusing on n-3-FA
supplementation in cancer patients suffering from weight
loss. This meta-analysis demonstrated a weight, appetite,
and life quality stabilizing effect of n-3-FA when giving a
minimum dose of 1.5 g per day over a period of at least
eight weeks. Newer interventional studies have confirmed
effects of n-3-FAs on weight stabilization and on the re-
duction of pro-inflammatory cytokines [15–19]. However,
there are controversial results. For example, Bruera et al.
[20] found no significant weight improvement in 60 cach-
ectic cancer patients taking EPA compared to placebo.
Similarly, Fearon et al. [21, 22] failed to demonstrate a
weight stabilizing effect of EPA in two studies (2.2 g and
2 g/4 g of EPA, respectively) supplementation, compared
to placebo or protein and energy dense supplements in
cachectic cancer patients. A common problem of these
studies was also the low compliance of patients to FO,
since the application ofFO is often accompanied by
gastrointestinal side effects like “fishy” regurgitation and
taste, nausea or flatulence if the dose exceeded the min-
imal effective dose of 1.5 g n-3 FA daily [23, 24]. To
avoid these side effects and to get better effects on body
weight-, appetite- and QoL, current studies investigated
n-3-FA given as marine phospholipids (MPL) [8] (and
not as FO), which mainly consist of n-3-FA-carrying
phospholipids. In the GI-tract, MPL are rapidly dis-
persed into the GI-fluids (as nanoparticles), which is in
contrast to FO which form larger oil-droplets. In
addition to the avoidance of large FO droplets mainly
localized on top of the gastric juice, nanodispersed MPL
will be much faster digested. This explains (i) the ob-
served better effects of MPL compared to FO, and (ii)
the reduced GI side effects. For this reason, patient’s
compliance to phospholipid bound n-3-FA is supposed
to be better than for FO formulation.
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Furthermore, several studies confirmed a higher inte-
gration of EPA and DHA into the cellular membranes,
when these FAs were given as phospholipids instead of
triglycerides [25, 26]. In this regard, studies of Burri
et al. [27], Schuchardt et al. [28], Ramprasath et al. [29]
and Ulven et al. [30] demonstrated a rapid supply and
high bioavailability of the n-3-FA bound to phospholipids
(interventional studies). In a four-week study with 24
healthy volunteers, Ramprasath et al. compared n-3-FA-
carrying phospholipids (krill oil) containing 600 mg of
EPA and DHA with FO and a placebo. They found a
higher n-3-FA uptake into the blood plasma, when com-
pared to n-3-FA as FO and to placebo (corn oil) [29]. A
few years earlier, Taylor et al. [8] investigated n-3-FA-carry-
ing phospholipids (marine phospholipids from salmon roe)
on 17 cachectic cancer patients over six weeks. They found
weight stabilization, and an improvement of appetite as
well as QoL even at a very low dose of FAs (corresponding
to 300 mg EPA and DHA per day), while the compliance
was high. Additionally, inflammation – measured as CRP
– decreased significantly duringthe intervention.
Since the study of Taylor was performed with patients
suffering from different cancer types and was a non-
controlled interventional trial, the aim of the present study
was to compare the effect of an identical composition (ra-
tio of DHA and EPA) and low amount of n-3-FA
(300 mg/day) either given as MPL- and as FO-formulation
on body weight, appetite global health (QoL) and on the
FA-profiles in plasma in pancreatic cancer patients. Both
interventions provided an amount of 300 mg EPA and
DHA daily, and were given either as MPL of as FO.
Methods
Study design and participants
We undertook a randomized, double-blind, controlled
trial in the International Pancreatic Cancer Center
Freiburg, in the Department of Oncology of the Medical
Center University of Freiburg, and the Freiburg Tumor
Biology Center between February 2011 and February
2011. Inclusion criteria were the following: pancreatic car-
cinoma, minimal age of 18 years, life expectancy of at least
three months, tumor associated weight loss of at least 5%
since diagnosis, Karnofsky score of at least 60%, no allergy
against fish or seafood, oral nutrition, no blood coagula-
tion disorders and no psychological disorder. Sixty pa-
tients were assessed for eligibility and allocated for
intervention. They were randomly assigned to receive ei-
ther MPL or FO. Randomization and masking was per-
formed with assignment envelopes containing the letter A
or B, which were prepared by a non-involved external
party (Membramed GmbH). Assignment code was re-
vealed at the end of the study by Membramed GmbH.
All of the participants gave informed written consent.
The study protocol was approved by the Ethics
Committee of the University of Freiburg, Germany
(Ethics Committee number 25/10, study number
DRKS0000345, UTN U1111–1113-6181).
Study protocol
Patients were asked to take one capsule (MPL or FO) three
times a day along with meals for six weeks. The FO and
MPL supplement consisted of similar amounts of n-3-fatty
acids (DHA and EPA) in the same ratio, and was offered as
500 mg soft gel capsules. FO capsules contained 60% of FO
and 40% of medium chain triglycerides (MCT) (6.9 g/100 g
eicosapentaenoic acid (EPA) and 13.6 g/100 g docosahexae-
noic acid (DHA)). MPL capsules contained 35% of n-3-FA-
phospholipids (mainly phosphatidylcholine) plus 65% of
neutral lipids (8,5 g/100 g EPA and 12.3 g/100 g DHA).
The final n-3-FA dose was 300 mg/day in both groups.
Both capsules were provided by Membramed AG, Ham-
burg, Germany. Concerning appearance, taste and smell,
there was no difference between the two preparations. As-
signment to each preparation was done in a double-blind
manner (FO: Capsules A; MPL: Capsules B).
The primary endpoint was the change of weight and ap-
petite. Secondary endpoints included QoL, fatty acid profile
of blood plasma, nutritional status, routine blood parame-
ters and adherence.
Each patient received a patient diary, in which daily body
weight, appetite, capsule intake and potential therapy
changes or abnormalities had to be reported. Patients were
mainly examined by one investigator twice, at the beginning
of the study (day 1; E1) and at the end of the study (after
six weeks; E2). Examinations included blood sampling for
routine analysis and for the determination of fatty acid pro-
files in blood plasma, a physical examination, measurement
of skinfold thickness with a caliper and completion of the
EORTC-QLQ-C30- (QoL in cancer patients), PAN26 (QoL
in pancreatic cancer patients)-, and a nutrition question-
naire. The EORTC-QLQ-C30-questionnaire consists of 30
questions, which allow the determination of the following
parameters: global health, functional (physical capacity and
physical capacity concerning family and job, hobbies and
emotions) and symptoms (pain, fatigue, nausea, diarrhea,
appetite loss, obstipation, breathlessness, financial impact,
sleeping disorders). The PAN26 questionnaire comprises of
26 questions assessing the parameters: pain, dietary
changes, altered bowel habit, jaundice, emotional problems
related to pancreatic cancer, cachexia, dry mouth, indiges-
tion, flatulence and taste changes.
Blood sampling and routine analysis
Blood samples were collected as EDTA blood (3 × S-
Monovette® 9 ml with 1.6 mg EDTA/ml blood, Sarstedt,
Nümbrecht, Germany) and centrifuged for 10 min at
2.000 rpm (805×g) at room temperature. The resulting
plasmas were stored in aliquots of 500 μl at −80 °C until
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analysis. Routine blood parameters were measured by
the clinical chemistry routine laboratory of the Tumor
Biology Center Freiburg (CRP, albumin, thrombocytes,
leukocytes, lipids (LDL, HDL, VLDL, total cholesterol,
triglycerides)and liver enzymes (GOT, GPT, CHE).
Evaluation of nutritional status
Patients were asked to report their daily body weight de-
termined by the same body balance. Skinfold thickness
was measured following the method of Durnin and
Womersley [31] with a caliper at three body points: the
upper arm, the back and on the iliac crest. Percentage of
body fat was determined independently of water accu-
mulation (edema or ascites).
Fatty acid profile of blood plasma
Fatty acid (FA) analysis of the polar lipids (phospholipids)
and non-polar lipids in patients plasma was performed as
described by Taylor et al., 2010 [8]. In brief, polar and
non-polar lipids were extracted with chloroform/metha-
nol, followed by the separation of phospholipids and non-
polar lipids using solid phase extraction with acetone. The
FA-amounts and –compositions of both groups of lipids
were measured by FA-methylation and subsequent gas
chromatography (GC).
Statistics
Based on experience from the previous Phosfood study
by Taylor et al. [8], sample size calculation resulted in16
patients and four drop outs per group, hence together 20
patients per group and 40 patients all in all. Because of the
unexpected high number of dropouts, the size of the
groups was raised to 60, altogether. Dropouts during the
intervention were not included in the analysis, resulting in
a per-protocol-analysis. Statistical analysis including t-test,
Mann-Whitney-U-test, Wilcoxon-test, Pearson-correlation
and Spearman-rang-correlation were performed with
SigmaStat 3.1 (Systat Software Inc., USA, 2004), Mystat
12.02.00 (student version, Systat) and OriginPro 8 SR0.
Results
Study cohort
Sixty patients were randomized and either assigned to
the FO (n = 31) or MPL (n = 29) group. Thirteen out of
31 patients of the FO group and 14 out of 29 patients of
the MPL group could not finish the study because of
non-compliance, progressive disease, gastrointestinal
side effects or death (Fig. 1). These patients were ex-
cluded from further analysis, since no data was available
for an intention-to-treat analysis. Eighteen patients of
the FO group and 15 patients of the MPL group com-
pleted the study and were examined for a second time.
In both groups 12 patients received chemotherapy and
one was treated with radiation, respectively. The
remaining patients were on supportive or alternative
therapies. Among the 18 patients of the FO group, there
were 15 patients with a palliative therapy approach. Only
three patients were treated with curative intention. In
the MPL group, six patients had a curative therapy re-
gime and nine patients had palliative treatment. Patients
of the MPL group had a higher mean body weight six
weeks before study start as well as at the beginning of
the study, compared to patients in the FO group. Their
mean BMI was also higher with 23.1 kg/m2 contrary to
21.3 kg/m2 (p = 0.02) (see Table 1). Besides that, there
were no significant differences between both groups.
Appetite/meal portions
Both groups of patients experienced stabilization of ap-
petite during the intervention. In accordance to that,
meal portions increased significantly in both interven-
tion groups (FO group (p = 0.02) and MPL-group
(p = 0.05)) (see Fig. 2).
Body weight
After six weeks of either FO or MPL intervention, both
groups took advantage of their respective dietary supple-
mentation, which became apparent in significant weight
stabilization in comparison to the weight loss before the
study (FO p = 0.001), MPL (p = 0.003), see Fig. 2). Body
weight (BW) changes for all patients who finished the
study are shown in fig. 2 (lower part) as dotted lines.
Nine out of 18 patients (50%) of the FO group gained
BW during the six week intervention. In the MPL group
seven out of 15 patients (47%) gained weight. In both
figures, the dotted lines show BW gain of two patients
each in both groups six weeks before the study, which
could be explained by water accumulation (edema and/
or ascites). Taking this into account, these patients lost
weight since their cancer diagnosis. As there was no
overall significant increase in body water, BW gain seen
in some of the patients can be explained by an increase
in fat mass (FM) or/and muscle mass (MM). Consider-
ing the whole body constitution, there was no significant
change in FM, MM and body water. With respect to the
BMI, the MPL group started with a more advantageous
body constitution than the FO group as the result of the
randomization. None of the patients in the FO group
had a BMI of 25 or higher. In contrast, six patients of
the MPL group had a BMI of at least 25, which can be
regarded as the upper limit of normal weight for healthy
people, and which served as a reference value to the
study. After the intervention, there was no significant
statistical difference of BMI in both groups.
Fatty acid composition
During six weeks of either MPL or FO intake, most fatty
acid profiles of both groups changed significantly. The
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average percentage of the anti-inflammatory docosa-
hexaenoic acid (DHA) increased significantly in both,
the plasma phospholipids as well as the the plasma
triglycerides (FO: p = <0.01, p = 0.000; MPL:
p = 0.005, p = 0.003; see Fig. 3, Table 2). The average
percentage of the anti-inflammatory eicosapentaenoic
acid (EPA) increased significantly in the plasma phos-
pholipids and plasma triglycerides of the FO group
(p = 0.002, p = 0.001; see Fig. 3 and Table 2). In con-
trast, in the MPL group, the average percentage of
EPA only increased significantly in the plasma triglyc-
erides (p = 0.01; see Fig. 3 and Table 2). The average
percentage of the pro-inflammatory arachidonic acid
(AA) decreased significantly in the phospholipid frac-
tion of plasma in the FO group (p = 0.05; see Fig. 3
and Table 2), while no significant change was
observed in the MPL group. Changes in fatty acid
profiles also became apparent by comparing the n6/
n3 ratios. Interestingly, the increase of EPA correlated
positively with the improvement of appetite in the FO
group (see Fig.3), in the MPL group there was no sig-
nificant correlation observed.
Routine laboratory parameters
The measured parameters and their change after
6 weeks of n-3-FA intake in both intervention
groups can be seen in Table 3. Routine blood pa-
rameters only show significant changes in the FO
group. HDL increased significantly from 42 mg/dl to
52 mg/dl (p = 0.002) in the FO group, the increase
in the MPL group was not significant. The measure-
ments at the beginning of the study showed that
seven out of 18 patients of the FO group had a
lower HDL level than recommended by the German
Lipid-Liga (men and women: > 40 mg/dl, www.lipid-
liga.de). In the MPL group there were only three out
of 15 patients with a low HDL value. After six weeks
patients in both, the FO and MPL group, who
started with a low HDL level, experienced a signifi-
cant increase of HDL during the intervention. On
the contrary, patients who started with a high HDL
did not experience a significant increase of HDL
values after the intervention. Aside from lipid pro-
file, there were also significant changes of GOT
(p = 0.03) and thrombocytes (p = 0.01) in the FO
group, but not in the MPL group.
Fig. 1 Patient enrollment: Flow chart of the Phosfood II dietary intervention60 patients were randomized and allocated to the FO (n = 31) or MPL (n = 29)
group. After six weeks of dietary intervention, 18 FO patients and 15 MPL patients could be analyzed (n = 33). FO = fishoil, MPL = marine phospholipids
Table 1 Baseline characteristics of the study population (n = 33)
Parameter FO MPL
Men/Women 7/11 9/6
Age (years) 70.3 ± 8.24 71.3 ± 7.51
BW 6 weeks before E1 (kg)* 62.9 ± 6.54 71.4 ± 15.3
BMI E1 (kg/m2)* 21.3 ± 1.73 23.7 ± 4.10
BW E1 (kg) 58.7 ± 4.93 67.6 ± 13.8
MM E1 (% BW) 21.5 ± 2.04 20.2 ± 2.98
FM E1 (% BW)* 25.2 ± 3.35 23.9 ± 2.74
BW without MM and FM
(=body water) E1 (%)*
53.3 ± 2.80 55.5 ± 8.53
*non- normally distributed, FO fishoil, MPL marine phospholipids, BW body
weight, MM muscle mass, FM fat mass, E1 examination 1
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Quality of life
In both groups there were no significant changes in QoL
after six weeks of n-3 FA supplementation, which was
measured with the EORTC-QLQ-C30-questionnaire, but
slight positive changes in all the major parameters “phys-
ical”, “role”, “social”, “pain”, “appetite loss” and “global
health” were observed. Using the PAN26 module, which
was especially designed for pancreatic cancer patients, the
Fig. 2 Body composition, food portions and body weight change. In both groups body composition remained nearly the same. Food portions
increased in both groups. FO and MPL patients could stabilize their body weight after six weeks of dietary intervention compared to six weeks before
intervention (left side FO. right side MPL). E1, E2 = examination1, 2, FO = fishoil. MPL = marine phospholipids, EPA = eicosapentaenoic acid
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parameter “hepatic”, decreased significantly in the MPL-
group. “Hepatic” represents involvement of hepatic dys-
functions in the context of pancreatic adenocarcinoma.
In addition, the observed increase of EPA in plasma
correlated with the “global health” in the FO group
(p = 0.05, r = 0.47, see Fig. 4). In the MPL group, no sig-
nificant correlation was observed (p = 0.12, r = 0.42).
There were no significant correlations between QoL and
AA or DHA in both groups.
Food questionnaire
Concerning food intake, there were no significant effects
of both n-3-FA-formulations. At the beginning of the
study (first examination) the n6/n3 ratio in the blood
lipids correlated significantly with the reported consump-
tion of fish (FO: r = −0.57, p = 0.02; MPL: r = 0.57,
p = 0.03). Also, a significant correlation between EPA and
fish intake at the first examination was observed in the
MPL group (r = 0.49, p = 0.06).
Compliance
In both groups the n-3 FA supplementation was highly ac-
cepted. In the FO group 94.8% and in the MPL group
97.6% of the patients took the supplement three times a
day. Four patients of the FO group reported experiencing
pyrosis, “fishy” regurgitation, loss of appetite, diarrhea and
increased bowel movement. In the MPL group only one
patient complained about diarrhea in the last week of the
study. Additionally, at the end of the study, patients were
asked if they would be willing to continue the n-3 FA sup-
plementation. Seven out of 18 patients (38.9%) of the FO
group argued for continuation of n-3-FA intake after the
study. In the MPL group eleven out of 15 patients (73.3%)
were willing to continue their supplementation. In some
Fig. 3 Fatty acid change. In both groups AA decreased after dietary intervention. The decrease was significant in the FO group. EPA and DHA
increased in both groups significantly. Appetite correlated positively with total EPA at the second examination (left side FO, right side MPL)
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cases, patients reported taking further medications along
with the study supplementation, which led them rather to
stop taking the n-3-FA formulations after the end of the
study.
Discussion
One possibility to treat cancer cachexia is the oral applica-
tion of anti-inflammatory n-3-FA. Usually, n-3-FA are
given as triglycerides (fish oil, FO) and, according to a
meta-analysis, the minimal effective dose is >1.5 g n-3-
FA/day (EPA and DHA) [12]. This meta-analysis included
17 clinical trials reporting on the effects of n-3-FA for
treating cachexia. Further studies showing positive effects
of n-3-FA given as FO at even higher doses have been
published [14–16, 20–22, 32–36].
Taylor et al. [8] investigated the effects of n-3-FA con-
taining marine phospholipids (MPL) on cachectic cancer
patients and found a weight stabilization effect at a five-
fold lower dose (300 mg n-3-FA/day), showing at the same
time a high tolerability. Ramprasath found similar results
with another n-3-FA containing phospholipid formulation
called krill oil. Based on these findings and in order to val-
idate the effects of low dose n-3-FA containing phospho-
lipids, we directly compared the effects of low dose FO
and MPL carrying the same n-3-FA-composition on cach-
ectic pancreatic cancer patients over six weeks.
Surprisingly, in both treatment arms the very low dos-
age of n-3-FA of 300 mg/day led to an impressive and
similar median weight stabilization. While this effect was
expected for the MPL group due to the study of Taylor
(MPL) and Ramprasath (krill oil), the effect was unex-
pected for the group taking FO, due to the evidence,
showing, that n-3-FA given as triglycerides will only be
effective at a dose of >1.5 g/day. One possible reason for
the weight stabilization effect in the FO group might be
due to the addition of medium chain triglycerides (MCT,
approximately 200 mg per capsule) to the FO formula-
tion. MCT had to be included into the FO supplementa-
tion to guarantee the same capsule volume as the ones
of the MPL supplementation. This was mandatory to
achieve MPL and FO capsules with the same appearance
and thus guarantee blinding. It was assumed that MCT
would have no effect on body weight at the low dose of
200 mg/capsule. However, some studies have found body
weight effects of high doses of MCT, as shown by
Fearon et al. [22] In that study, MCT (given as placebo)
was compared to the intake of 2 g and 4 g of EPA per
day. The exact amount of MCT was not mentioned in
his publication, but it can be assumed, that it was also 2
and 4 g,. Furthermore, MCT have often been success-
fully applied to treat weight loss in several studies not
focusing on the effects of n-3-FA [37–39]. This seems
plausible because of their better water solubility com-
pared to long chain triglycerides and their faster intes-
tinal absorption. MCT are an important element of diets
for patients suffering from pancreatic insufficiency, cys-
tic fibrosis as well as short barrel syndrome, as they
serve for rapid energy generation [40–44]. The men-
tioned effects have been observed at much higher MCT
doses (2.8 g MCT per day, Bounous et al. [43]), than ad-
ministered in the current study.
The similar effects of low dose MPL and FO on the pa-
tient’s weight are not a random or placebo effect, which
can be shown by the similar increase of n-3-FA in plasma
triglycerides and phospholipids in both study groups. This
Table 2 Mean plasma levels of n-3 and n-6 fatty acids in the FO
group (n = 18) and MPL group (n = 15) at the beginning of the
study (E1) and after 6 weeks (E2). All values are given in % of
total fatty acids)
Fatty acid (mean) E1 E2 P-value change
EPA triglyceride
FO 0.55 ± 0.22 0.89 ± 0.31 0.001** +62%
MPL 0.76 ± 0.51 1.05 ± 0.44 0.01** +38%
EPA phospholipid*
FO 0.72 ± 0.31 1.16 ± 0.39 0.002** +61%
MPL 1.08 ± 0.75 1.25 ± 0.53 0.20 +16%
EPA total*
FO 1.27 ± 0.51 2.05 ± 0.68 0.001** +61%
MPL 1.83 ± 1.23 2.31 ± 0.91 0.034** +55%
DHA triglyceride*
FO 0.71 ± 0.24 1.03 ± 0.36 <0.001** +23%
MPL 0.94 ± 0.39 1.14 ± 0.30 0.003** +14%
DHA phospholipid
FO 2.55 ± 0.73 3.46 ± 1.14 0.000** +36%
MPL 3.14 ± 0.83 3.69 ± 0.70 0.005** +18%
DHA total
FO 3.26 ± 0.84 4.49 ± 1.41 0.000** +38%
MPL 4.07 ± 1.17 4.83 ± 0.96 0.004** +19%
AA triglyceride
FO 4.43 ± 1.08 4.12 ± 1.02 0.09 -7%
MPL 4.24 ± 1.15 3.94 ± 0.99 0.296 -7%
AA phospholipid*
FO 9.07 ± 1.82 8.34 ± 1.45 0.05** -8%
MPL 8.71 ± 1.37 8.51 ± 1.60 0.256 −2%
AA total
FO 13.5 ± 2.47 12.5 ± 2.27 0.027** -7%
MPL 13.0 ± 2.02 12.4 ± 2.37 0.22 −5%
n:6/n:3 (total)
FO 3.13 ± 0.82 2.17 ± 1.11 <0.001** -31%
MPL 2.44 ± 0.78 1.82 ± 0.49 0.000** −25%
*non- normally distributed, EPA eicosapentaenoic acid, DHA docosahexaenoic
acid, AA arachidonic acid
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allows us to assume, that the observed low dose MCT-
effect is not due to the extra calories, but possibly due to a
faster resorption of the n-3-FA induced by MCT in the
FO group. One possible mechanism might be a better (or
faster) availability of energy for mucosa cells, accelerating
thereby the uptake of n-3-FA into chylomicrons. In
Table 3 Basic blood parameters in the FO group (n = 18) and MPL group (n = 15) at the beginning of the study (E1) and after
6 weeks (E2)
Blood parameter (mean) E1 E2 P-value change
CRP (mg/dl)*
FO 33.7 ± 65.8 15.6 ± 21.3 0.98 -54%
MPL 30.6 ± 68.9 10.4 ± 11.5 0.95 −66%
Albumin (g/dl)
FO 3.73 ± 0.64 3.76 ± 0.63 0.76 +0,8%
MPL 3.69 ± 0.68 3.89 ± 0.55 0.31 +5,4%
Leukocytes (n/nl)*
FO 7.78 ± 4.3 7.46 ± 4.93 0.59 -4%
MPL 7.88 ± 4.90 6.68 ± 2.09 0.40 −15%
Thrombocytes (n/nl)
FO 296.3 ± 151.0 244.1 ± 121.1 0.01** -18%
MPL 363.5 ± 254.6 270.9 ± 113.1 0.12 −25%
Triglycerides (mg/dl)
FO 112.1 ± 45.2 99.3 ± 45.1 0.33 -11%
MPL 130.1 ± 78.0 116.6 ± 41.9 0.64 −10%
Cholesterol (mg/dl)
FO 159.6 ± 47.0 161.8 ± 47.0 0.78 +1%
MPL 170.5 ± 42.7 179.2 ± 35.7 0.31 +5%
LDL (mg/dl)
FO 90.8 ± 34.4 86.9 ± 39.4 0.54 -4%
MPL 99.7 ± 33.9 109.8 ± 33.6 0.11 +10%
HDL (mg/dl)*
FO 51.3 ± 24.8 62.6 ± 28.7 0.00** +22%
MPL 48.1 ± 16.4 50.4 ± 8.64 0.48 +5%
VLDL (mg/dl)*
FO 20.4 ± 13.5 18.0 ± 9.4 0.29 -12%
MPL 23.9 ± 16.6 21.6 ± 10.9 0.74 -10%
GOT (U/l)*
FO 39.3 ± 35.6 42.6 ± 32.3 0.03** +8%
MPL 26.3 ± 7.41 29.4 ± 7.99 0.14 +12%
GPT (U/l)*
FO 41.4 ± 44.9 48.4 ± 48.4 0.18 +17%
MPL 25.7 ± 8.99 36.0 ± 27.5 0.12 +40%
CHE (U/l)*
FO 5558.8 ± 1880.3 5788.9 ± 1780.3 0.30 +4%
MPL 5388.9 ± 1630.8 5817.5 ± 1282.2 0.18 +8%
Ratio LDL/HDL
FO 2.05 ± 0.90 1.63 ± 0.91 0.01** -20%
MPL 2.6 ± 2.4 2.3 ± 1.04 0.60 -12%
E1, E2 = examination1, 2, * non-normally distributed, ** statistically significant
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contrast, the similar weight stabilization effect of MPL
(without MCT) might be explained by a faster digestion
and subsequent resorption of free n-3-FA or n-3-FA-car-
rying lyso-phospholipids, due to the expected rapid forma-
tion of a lipid emulsion of the MPL-contents in the gastric
fluids. This emulsion consists most probably of rather
small lipid particles, including also nanoparticles. The rea-
son for that might be the fact that the ratio of the ‘emulsi-
fier’ in the MPL formulation – the phospholipids – is
much higher (~35%) than the ratio of phospholipids in
commercial lipid emulsions for parenteral nutrition, which
is typically about 3%. In MPL the ratio of phospholipids to
triglycerides is more than ten times higher, which probably
results in the self-assembly of very small lipid droplets.
Those nanoparticles can easily be reached and hydrolyzed
by lipolytic enzymes like pancreatic phospholipase A2 and
pancreatic lipase [8].
The formation of an emulsion instead of forming lar-
ger lipid droplets in the gastric fluids also explains the
better tolerability and fewer gastrointestinal side effects
of MPL when compared to FO. This was also observed
by Bruera et al. [20] and Burns et al. [23] As shown in
that study, even when using a very low dose of FO, the
tolerability of MPL was better than that of FO. We could
observe only few side effects and a very high compliance
in the MPL group. Patients were highly satisfied with
this supplement and about 97.6% of the MPL group de-
clared their wish to continue capsule intake after the
end of the study.
Regarding body composition, the patients in the MPL
group did not gain weight through accumulation of water,
but by an increase of protein. For example, the female pa-
tient who had the lowest BMI at the beginning of the
study (18.4 kg/m2) and who gained the most weight of all
patients, increased her protein ratio by 10%. This
corresponded to 84% of her weight gain, leading to a final
BMI of 19.7 kg/m2. On the contrary another patient of the
MPL group, who had the highest BMI at the beginning of
the study (35.9 kg/m2) lost further 7 kg of body weight,
which was almost completely water (final BMI: 33.3 kg/
m2). On the other hand, patients in the FO group gained
body water and lost protein, which was confirmed by skin-
fold thickness measurements. Further studies are neces-
sary to confirm and explain these observations.
In terms of appetite, there was no statistical significant
increase of appetite in both groups. This favors the hy-
pothesis, that the observed weight stabilization was
mainly caused by the suppression of inflammatory pro-
cesses by n-3-FA and not due to a higher food intake.
As the increase of EPA correlated positively with the im-
provement of appetite in the FO group, a possible
appetite-stimulating effect of EPA can be discussed.
However, since this effect could not be seen in the MPL
group, this possibility remains unclear.
QoL was measured with two questionnaires (EORTC-
QLQ-C30 and module PAN26). The analyzed parame-
ters did not change significantly in both patient groups.
Never the less, despite not significant, all the parameters
have changed positively in both groups, assuming that
there might be a positive effect of n-3-FA on QoL. These
not significant improvements of QoL are in agreement
with the findings of Taylor et al. [8] That there indeed
might be an effect of n-3-FA on QoL is illustrated by the
finding of a significant positive correlation between the
general QoL-parameter “global health” and the increase
of EPA in blood plasma after taking FO. Against our
working hypothesis of a stronger effect of MPL on qual-
ity of life, when compared to FO, FO supplementation
also results in an increase of the parameter “global
health”. A possible reason for that could be the above
Fig. 4 Correlation between the parameter “global health” and the total change of EPA. In the FO group, the change of total EPA correlated positively
(p = 0.05) with the parameter “global health” of the EORTC-QLQ-C30 questionnaire, which stands for quality of life (QoL). In the MPL group, correlation
was not significant (p = 0.12), (left side FO, right side MPL)
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discussed addition of MCT, which caused a similar in-
crease of FO-bound n-3-FA in the blood plasma com-
pared to MPL. Similar results were reported by Fearon
et al. [22], who reported an improvement of “physical
function” (as a component of “global health”) in patients
taking FO supplementation. In a further study of Fearon
et al. [21] with cachectic pancreatic carcinoma patients,
the researchers found a significant positive correlation
between FO consumption and QoL, as well as between
QoL and gain of body weight. Furthermore, the param-
eter “hepatic”, measured by the PAN26 module, slightly
decreased in the MPL group, which indicated less
gastrointestinal dysfunctions. This might be explained by
the liver protecting effect of the applied phospholipids:
Gundermann et al. [45] summarized the beneficial ef-
fects of essential phospholipids from soybean in liver
diseases. In his review he reported positive effects of
phospholipids on inflammation, fibrosis and intoxication
of the liver without relevant side effects [45]. If the ef-
fects of MPL on liver function are based on the phos-
pholipids themselves or on a combination of
phospholipids plus anti-inflammatory fatty acids, is not
clear. Although the formulation used in this study is
based on marine phospholipids, the active component
remains the same, explaining the positive change of the
parameter “hepatic” in the MPL group of this study.
Conclusion
N-3-fatty acids, given as marine phospholipids or as fish
oil in combination with medium chain triglycerides, are
highly accepted and cause a significant weight
stabilization effect after a period of six weeks at a very
low dose of 300 mg n-3-FA/day in cachectic pancreatic
carcinoma patients. In terms of weight stabilization, ap-
petite and quality of life, effects of FO were similar to
the effects of MPL, probably due to unexplained effects
of low dosed MCT. However, MPL was better tolerated
and had a higher acceptance in the study group.
Reflecting the higher compliance to MPL and the un-
expected weight stabilizing effect of FO (with low dose
of MCT), the question of an even more effective n-3-
fatty acid formulation composed of MPL and MCT
arises. Further studies are necessary to investigate the ef-
fects of MPL in a larger study population as well as to
investigate the actual weight stabilizing mechanism of
MCT.
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